CA2581606A1 - Carrier-free composition for the treatment of onychomycosis - Google Patents
Carrier-free composition for the treatment of onychomycosis Download PDFInfo
- Publication number
- CA2581606A1 CA2581606A1 CA002581606A CA2581606A CA2581606A1 CA 2581606 A1 CA2581606 A1 CA 2581606A1 CA 002581606 A CA002581606 A CA 002581606A CA 2581606 A CA2581606 A CA 2581606A CA 2581606 A1 CA2581606 A1 CA 2581606A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- ingredients
- carrier
- mixture
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 208000010195 Onychomycosis Diseases 0.000 title abstract description 5
- 201000005882 tinea unguium Diseases 0.000 title abstract description 5
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000004615 ingredient Substances 0.000 claims abstract description 21
- 239000007788 liquid Substances 0.000 claims abstract description 14
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 13
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims abstract description 13
- 241000723346 Cinnamomum camphora Species 0.000 claims abstract description 13
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000005844 Thymol Substances 0.000 claims abstract description 13
- 229960000846 camphor Drugs 0.000 claims abstract description 13
- 229930008380 camphor Natural products 0.000 claims abstract description 13
- 229940041616 menthol Drugs 0.000 claims abstract description 13
- 229960000790 thymol Drugs 0.000 claims abstract description 13
- 244000166124 Eucalyptus globulus Species 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 13
- 239000003921 oil Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 210000004906 toe nail Anatomy 0.000 claims description 3
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 239000012230 colorless oil Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 abstract description 2
- 208000026721 nail disease Diseases 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 3
- 210000000282 nail Anatomy 0.000 description 3
- 241001353193 Agromyces terreus Species 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 241000222173 Candida parapsilosis Species 0.000 description 2
- 241000223221 Fusarium oxysporum Species 0.000 description 2
- 241000690372 Fusarium proliferatum Species 0.000 description 2
- 241000893980 Microsporum canis Species 0.000 description 2
- 241000509463 Neoscytalidium hyalinum Species 0.000 description 2
- 241000228417 Sarocladium strictum Species 0.000 description 2
- 241000825258 Scopulariopsis brevicaulis Species 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 1
- 241000228431 Acremonium chrysogenum Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241001480036 Epidermophyton floccosum Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 244000165852 Eucalyptus citriodora Species 0.000 description 1
- 235000004722 Eucalyptus citriodora Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 241001547451 Neoscytalidium dimidiatum Species 0.000 description 1
- 239000006159 Sabouraud's agar Substances 0.000 description 1
- 241000223255 Scytalidium Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000002802 antimicrobial activity assay Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K31/125—Camphor; Nuclear substituted derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
A composition for the treatment of onychomycosis (fungal nail disease) is described. The composition consists essentially of thymol, camphor, menthol and Eucalyptus citridiora as a colorless liquid oil without any carrier or solvent for these ingredients.
Description
CARRIER-FREE COMPOSITION FOR THE TREATMENT
OF ONYCHOMYCOSIS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] Not Applicable STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT
OF ONYCHOMYCOSIS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] Not Applicable STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT
[0002] Not Applicable STATEMENT REGARDING GOVERNMENT RIGHTS
[0003] Not Applicable BACKGROUND OF THE INVENTION
(1) Field of the Invention [0004] The present invention relates to a carrier-free composition which is an onychomycosis (fungal nail disease) therapeutic agent. In particular, the present invention relates to a composition consisting essentially of thymol, camphor, menthol and Eucalyptus citridiora oil.
(2) Description of the Related Art [0005] U.S. Patent No. 6,344,190 to Nair et al describes the use of camphor, menthol, eucalyptus and thymol with a carrier which is a solvent for the ingredients;
particularly, an ester of an alcohol such as isoamyl alcohol. This was done to solubilize the ingredients. It was thought that the carrier was necessary for this purpose.
OBJECTS
(1) Field of the Invention [0004] The present invention relates to a carrier-free composition which is an onychomycosis (fungal nail disease) therapeutic agent. In particular, the present invention relates to a composition consisting essentially of thymol, camphor, menthol and Eucalyptus citridiora oil.
(2) Description of the Related Art [0005] U.S. Patent No. 6,344,190 to Nair et al describes the use of camphor, menthol, eucalyptus and thymol with a carrier which is a solvent for the ingredients;
particularly, an ester of an alcohol such as isoamyl alcohol. This was done to solubilize the ingredients. It was thought that the carrier was necessary for this purpose.
OBJECTS
[0006] It is therefore an object of the present invention to provide a carrier-free composition wherein the ingredients are solubilized to provide a clear solution. It is further an object of the present invention to provide a method for the preparation of the composition. It is also an object of the present invention to provide a method for the use of the composition. These and other objects will become increasingly apparent by reference to the following description.
SUMMARY OF THE INVENTION
SUMMARY OF THE INVENTION
[0007] The present invention relates to a composition which consists essentially of (1) thymol, (2) camphor, (3) menthol and (4) Eucalyptus citridiora oil as ingredients in amounts which provide a colorless liquid in absence of a carrier. Preferably, the composition contains equal parts by weight of the ingredients. Further, the composition of the colorless liquid has been provided by a method which comprises stirring ingredients (1) to (3) into ingredient (4) to provide the colorless liquid. Still further, the composition of the ingredients (1) to (3) are introduced into ingredient (4) and then the mixture is heated to produce the colorless liquid. Preferably, the composition of the mixture has been heated up to about 80 C.
[0008] Further, the present invention relates to a method for the preparation of a pharmaceutical composition which comprises: mixing (1) thymol, (2) camphor, and (3) menthol into (4) Eucalyptus citridiora oil; and treating the mixture to provide a colorless oil. Preferably, the present invention relates to the method wherein the treating is by heating the mixture. Still further, the present invention relates to the method wherein the treating is by mixing the ingredi,ents over a period of time to provide the colorless mixture.
[0009] Further still, the present invention relates to a method of treating toenail fungal infections which comprises: applying a composition which consists essentially of (1) thymol, (2) camphor, (3) menthol, and (4) Eucalyptus citridiora oil as ingredients in amounts which provide a colorless liquid in absence of a carrier.
Preferably, the method of the composition contains equal parts of the ingredients.
Preferably, the method of the composition contains equal parts of the ingredients.
[0010] The substance and advantages of the present invention will become increasingly apparent by reference to the following description.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] Equal weights of thymol, camphor, menthol and Eucalyptus citridiora oil were used to formulate the TNF
therapeutic agent resulting to a clear liquid that penetrates the cuticles and nails. The Eucalyptus citridiora oil was weighed first and stirred with equal weights of solid thymol, menthol and camphor. The mixture was then warmed to 80 C till it forms a colorless liquid or stir at room temperature till the solids dissolve to form a colorless.liquid. The resulting product is easy to apply on infected nails using a nail polish applicator or by a cotton swab.
therapeutic agent resulting to a clear liquid that penetrates the cuticles and nails. The Eucalyptus citridiora oil was weighed first and stirred with equal weights of solid thymol, menthol and camphor. The mixture was then warmed to 80 C till it forms a colorless liquid or stir at room temperature till the solids dissolve to form a colorless.liquid. The resulting product is easy to apply on infected nails using a nail polish applicator or by a cotton swab.
[0012] Tests were performed with the composition on toenail fungi as follows:
[0013] Components in the formulation were equal weights of the following compounds 1-4:
1. Camphor OH
2. Menthol 3. Thymol 4. E. citridiora oil [0014] Microbial cultures. All organisms, except the Fusarium and Candida spp., were purchased from American Type Culture Collection (ATCC), Manassas, Virginia, USA. The Fusarium and Candida spp. were Michigan State University (MSU) strains (Nair, M.G., Putnam, A.R., Mishra, S.K., Mulks, M.H., Taft, W.H., Keller, J.E., Miller, J.R., Zhu, P.P., Meinhart, J.D., Lynn, D.G. 1989. Fae,riefungin: A new broad-spectrum antibiotic from Streptomyces griseus var.
autotrophicus. J Nat Prod 52: 797-809).
1. Camphor OH
2. Menthol 3. Thymol 4. E. citridiora oil [0014] Microbial cultures. All organisms, except the Fusarium and Candida spp., were purchased from American Type Culture Collection (ATCC), Manassas, Virginia, USA. The Fusarium and Candida spp. were Michigan State University (MSU) strains (Nair, M.G., Putnam, A.R., Mishra, S.K., Mulks, M.H., Taft, W.H., Keller, J.E., Miller, J.R., Zhu, P.P., Meinhart, J.D., Lynn, D.G. 1989. Fae,riefungin: A new broad-spectrum antibiotic from Streptomyces griseus var.
autotrophicus. J Nat Prod 52: 797-809).
[0015] Antimicrobial assay.M. canis (ATCC 42888), E.
floccosum (ATCC 44685), F. oxysporum (MSU strain), F.
proliferatum (MSU strain), A. chrysogenum (ATCC 22571), A.
strictum (ATCC 46646), A. terreus (ATCC 52293), and A.
flavus (ATCC 60040) were cultured in Petri dishes containing PDA medium (20 mL). T. rubrum (ATCC 28202), T.
mentagrophytes (ATCC 42194), S. brevicaulis (ATCC 36139), and S. dimidiatum (ATCC 46921) were cultured in Petri dishes containing Emmon's modification of Sabouraud's agar medium (20 mL). S. hyalinum (ATCC 66093) was cultured in Petri dishes containing Malt extract agar medium (20 mL).
The test organisms C. albicans (MSU strain), C. kruseii (MSU
strain), and C. parapsilosis (MSU strain) were cultured in Petri dishes containing YMG media (20 mL).
floccosum (ATCC 44685), F. oxysporum (MSU strain), F.
proliferatum (MSU strain), A. chrysogenum (ATCC 22571), A.
strictum (ATCC 46646), A. terreus (ATCC 52293), and A.
flavus (ATCC 60040) were cultured in Petri dishes containing PDA medium (20 mL). T. rubrum (ATCC 28202), T.
mentagrophytes (ATCC 42194), S. brevicaulis (ATCC 36139), and S. dimidiatum (ATCC 46921) were cultured in Petri dishes containing Emmon's modification of Sabouraud's agar medium (20 mL). S. hyalinum (ATCC 66093) was cultured in Petri dishes containing Malt extract agar medium (20 mL).
The test organisms C. albicans (MSU strain), C. kruseii (MSU
strain), and C. parapsilosis (MSU strain) were cultured in Petri dishes containing YMG media (20 mL).
[0016] The cells from a fully- grown plate of each organism were suspended in saline solution (5 mL) and diluted to obtain 5 x 106 CFU/mL using a hemacytometer. 50 ~L of this suspension was used to inoculate I mL of respective growth medium of each test organism. Test formulation was added to the inoculated tubes at concentrations ranging from 250 to 5 ~1/mL. The tubes containing cell cultures and compounds were incubated at 27 C for 72- 96 h. At the end of the incubation period, the tubes were examined for growth of the organism and further monitored for 7 days after which they were recorded for growth or no growth. The concentration at which no growth was observed or minimum concentration for 100 % inhibition (MIC loo) is shown in Table 1 for each organism.
Table 1. MICIoo ( g/mL) for the mixture containing equal weights of camphor, menthol, thymol and Eucalyptus citriodora oil against organisms causing onychomycosis.
Organism MIC
>20 Acremonium chrysogenunz A. strictum >_20 AspergilZus flavus >30 _30 A. terreus Candida albicans' _50 C. kruseii >_50 C. parapsilosis >_50 Epidernzoplzyton floccosum ?30 Fusarium oxysporum ?30 F. proliferatum >_30 Microsporum canis ?40 _30 Scopulariopsis brevicaulis >_30 Scytalidium dinzidiatum S. hyalinum >_30 Trichophyton mentagroplZytes ~:30 T. rubruni >_30 [0017] The composition had a very broad spectrum of activity as can be seen from the results.
Table 1. MICIoo ( g/mL) for the mixture containing equal weights of camphor, menthol, thymol and Eucalyptus citriodora oil against organisms causing onychomycosis.
Organism MIC
>20 Acremonium chrysogenunz A. strictum >_20 AspergilZus flavus >30 _30 A. terreus Candida albicans' _50 C. kruseii >_50 C. parapsilosis >_50 Epidernzoplzyton floccosum ?30 Fusarium oxysporum ?30 F. proliferatum >_30 Microsporum canis ?40 _30 Scopulariopsis brevicaulis >_30 Scytalidium dinzidiatum S. hyalinum >_30 Trichophyton mentagroplZytes ~:30 T. rubruni >_30 [0017] The composition had a very broad spectrum of activity as can be seen from the results.
[0018] It is intended that the foregoing description be only illustrative of the present invention and that the present invention be limited only by the hereinafter appended claims.
Claims (10)
1. A composition which consists essentially of (1) thymol, (2) camphor, (3) menthol and (4) Eucalyptus citridiora oil as ingredients in amounts which provide a colorless liquid in absence of a carrier.
2. The composition of Claim 1 wherein the composition contains equal parts by weight of the ingredients.
3. The composition of Claims 1 or 2 wherein the colorless liquid has been provided by stirring ingredients (1) to (3) into ingredient (4) to provide the colorless liquid.
4. The composition of Claims 1 or 2 wherein the ingredients (1) to (3) are introduced into ingredient (4) and then the mixture is heated to produce the colorless liquid.
5. The composition of Claims 1 or 2 wherein the mixture has been heated up to about 80°C.
6. A method for the preparation of a pharmaceutical composition which comprises:
(a) mixing (1) thymol, (2) camphor, and (3) menthol into (4) Eucalyptus citridiora oil; and (b) treating the mixture to provide a colorless oil.
(a) mixing (1) thymol, (2) camphor, and (3) menthol into (4) Eucalyptus citridiora oil; and (b) treating the mixture to provide a colorless oil.
7. The method of Claim 6 wherein the treating is by heating the mixture.
8. The method of Claim 6 wherein the treating is by mixing the ingredients over a period of time to provide the colorless mixture.
9. A method of treating toenail fungal infections which comprises:
applying a composition which consists essentially of (1) thymol, (2) camphor, (3) menthol, and (4) Eucalyptus citridiora oil as ingredients in amounts which provide a colorless liquid in absence of a carrier.
applying a composition which consists essentially of (1) thymol, (2) camphor, (3) menthol, and (4) Eucalyptus citridiora oil as ingredients in amounts which provide a colorless liquid in absence of a carrier.
10. The method of Claim 9 wherein the composition contains equal parts of the ingredients.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2004/031630 WO2006036144A1 (en) | 2004-09-24 | 2004-09-24 | Carrier-free composition for the treatment of onychomycosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2581606A1 true CA2581606A1 (en) | 2006-04-06 |
Family
ID=36119190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002581606A Abandoned CA2581606A1 (en) | 2004-09-24 | 2004-09-24 | Carrier-free composition for the treatment of onychomycosis |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1796703A4 (en) |
| JP (1) | JP2008514596A (en) |
| CA (1) | CA2581606A1 (en) |
| WO (1) | WO2006036144A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL1036661C2 (en) | 2009-03-04 | 2010-09-07 | Serrix B V | Anti-fungal compounds & compositions. |
| DE202010012041U1 (en) | 2010-08-31 | 2010-11-18 | Sanderstrothmann Gmbh | Preparation for nail care |
| CN103893599A (en) * | 2014-04-12 | 2014-07-02 | 张军 | External traditional Chinese medicine lotion for treating onychomycosis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04154719A (en) * | 1990-10-19 | 1992-05-27 | Hiroshi Kikuchi | Athlete's foot drug |
| KR20010013210A (en) * | 1997-05-30 | 2001-02-26 | 데이비드 엠 모이어 | Disinfecting compositions and processes for disinfecting surfaces |
| JP2000128800A (en) * | 1998-10-16 | 2000-05-09 | Hideyo Yamaguchi | Prevention of infection of dermatophytosis and/or its treatment and tool and material for treatment |
| US6344190B1 (en) * | 1999-02-08 | 2002-02-05 | Board Of Trustees Of Michigan State University | Method and compositions for treatment of fungal nail disease |
| US6436424B1 (en) * | 2000-03-20 | 2002-08-20 | Biosphere Medical, Inc. | Injectable and swellable microspheres for dermal augmentation |
| JP2003073290A (en) * | 2001-08-31 | 2003-03-12 | Kao Corp | External preparation composition |
-
2004
- 2004-09-24 CA CA002581606A patent/CA2581606A1/en not_active Abandoned
- 2004-09-24 WO PCT/US2004/031630 patent/WO2006036144A1/en active Application Filing
- 2004-09-24 EP EP04789085A patent/EP1796703A4/en not_active Withdrawn
- 2004-09-24 JP JP2007533444A patent/JP2008514596A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008514596A (en) | 2008-05-08 |
| EP1796703A1 (en) | 2007-06-20 |
| WO2006036144A8 (en) | 2007-06-14 |
| AU2004323577A1 (en) | 2006-04-06 |
| EP1796703A4 (en) | 2009-07-01 |
| WO2006036144A1 (en) | 2006-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10980846B2 (en) | Use of gram negative species to treat atopic dermatitis | |
| Orafidiya et al. | The formulation of an effective topical antibacterial product containing Ocimum gratissimum leaf essential oil | |
| Ramsewak et al. | In vitro antagonistic activity of monoterpenes and their mixtures against ‘toe nail fungus’ pathogens | |
| Khosravi et al. | Zataria multiflora cream for the treatment of acute vaginal candidiasis | |
| US20210169943A1 (en) | Use of gram negative species to treat atopic dermatitis | |
| US20200254029A1 (en) | Use of gram negative species to treat atopic dermatitis | |
| US7341747B2 (en) | Carrier-free composition for the treatment of onychomycosis | |
| Kotnik et al. | Terbinafine hydrochloride treatment of Microsporum canis experimentally-induced ringworm in cats | |
| Gayatri et al. | Novel thiazolinyl-picolinamide-based palladium (II) complex extenuates the virulence and biofilms of vulvovaginal candidiasis (VVC) causing Candida | |
| Ansari et al. | Design and evaluation of topical herbal antifungal stick containing extracts of Rhinacanthus nasutus | |
| CA2581606A1 (en) | Carrier-free composition for the treatment of onychomycosis | |
| WO2010132122A2 (en) | Compositions and products containing cycloaliphatic diol antimicrobial agents and methods of using the compositions and products | |
| AU2004323577B2 (en) | Carrier-free composition for the treatment of onychomycosis | |
| US10736938B2 (en) | Method for the treatment of acne | |
| US20240277782A1 (en) | Compositions and methods for microbial treatment of skin disorders | |
| EP4213949A1 (en) | Use of a preservative composition to preserve the eubiosis of skin tissue and scalp | |
| Bairagi et al. | Identification of bacterial population from diabetic wound of mice to study the bactericidal efficacy of green synthesized silver nanoparticle by saraca asoca bark extract | |
| KR20120086123A (en) | External Composition for Skin Having Antibacterial Activities | |
| Abdul-Hussain et al. | Crude aqueous Proteus mirabilis extract with quorum sensing inhibitory activity can increase the susceptibility of multidrug resistant Pseudomonas aeruginosa to antimicrobials | |
| ALAHMAD et al. | IN VITRO ANTIFUNGAL ACTIVITY OF THYME OIL AGAINST CANDIDA ALBICANS ISOLATED FROM NAIL FUNGUS (ONYCHOMYCOSIS) | |
| KR20240119515A (en) | Topical drug for treating acne | |
| Shaqra et al. | In vitro Inhibition of Candida Species by Aqueous Garlic Extract in Gel and Lotion: Problem of Stability | |
| Al-Toma0T et al. | The preparation and Evaluation of Some Metronidazole Formulations as Gels and The study of Their Medicinal Activities Against Pathogenetic Microorganisms Causing Dermatitides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |